Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

In a report released today, Terence Flynn from Morgan Stanley reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report), with a ...

Begin your TipRanks Premium journey today. Eli Lilly & Co (LLY) Company Description: Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical ...

Eli Lilly saw Mounjaro sales climb by about 114% ... guidance and offered guidance for the new year, which many investors found disappointing. Sales are still booming—chairman and CEO David ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

SAN FRANCISCO — Eli Lilly’s chief scientific officer said ... has a high selectivity for the mutant form of a protein found in some cancers, without targeting the normal version found in ...

Eli Lilly's sales growth is coming short of expectations, which is a problem considering its valuation. The company does have a vast lineup and a deep pipeline that go beyond diabetes and obesity.

Over the past six months, Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the ...